上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
21期
9-13,19
,共6页
艾滋病%抗病毒治疗%特殊人群
艾滋病%抗病毒治療%特殊人群
애자병%항병독치료%특수인군
AIDS%antiretroviral therapy%special population
抗病毒治疗的实施和广泛应用已使艾滋病从一种致死性疾病变为一种可以治疗的慢性疾病。随着基础和临床研究的进一步深入,艾滋病抗病毒治疗不断取得新进展。近年来,人们在艾滋病抗病毒治疗的时机与方案、抗病毒治疗的随访、特殊人群和合并其他感染患者的抗病毒治疗等方面提出了很多新的观点。目前认为,所有艾滋病患者均应尽早接受抗病毒治疗,而新型抗艾滋病药物的上市为临床治疗提供了新的选择。有关研究尤其是大型、随机、对照临床试验结果将不断更新和优化艾滋病抗病毒治疗方案,进而不断提高临床抗艾滋病治疗疗效,并使艾滋病最终被治愈也成为可能。为更多的艾滋病患者提供更高效的抗病毒治疗是目前改善艾滋病患者预后的最现实途径。
抗病毒治療的實施和廣汎應用已使艾滋病從一種緻死性疾病變為一種可以治療的慢性疾病。隨著基礎和臨床研究的進一步深入,艾滋病抗病毒治療不斷取得新進展。近年來,人們在艾滋病抗病毒治療的時機與方案、抗病毒治療的隨訪、特殊人群和閤併其他感染患者的抗病毒治療等方麵提齣瞭很多新的觀點。目前認為,所有艾滋病患者均應儘早接受抗病毒治療,而新型抗艾滋病藥物的上市為臨床治療提供瞭新的選擇。有關研究尤其是大型、隨機、對照臨床試驗結果將不斷更新和優化艾滋病抗病毒治療方案,進而不斷提高臨床抗艾滋病治療療效,併使艾滋病最終被治愈也成為可能。為更多的艾滋病患者提供更高效的抗病毒治療是目前改善艾滋病患者預後的最現實途徑。
항병독치료적실시화엄범응용이사애자병종일충치사성질병변위일충가이치료적만성질병。수착기출화림상연구적진일보심입,애자병항병독치료불단취득신진전。근년래,인문재애자병항병독치료적시궤여방안、항병독치료적수방、특수인군화합병기타감염환자적항병독치료등방면제출료흔다신적관점。목전인위,소유애자병환자균응진조접수항병독치료,이신형항애자병약물적상시위림상치료제공료신적선택。유관연구우기시대형、수궤、대조림상시험결과장불단경신화우화애자병항병독치료방안,진이불단제고림상항애자병치료료효,병사애자병최종피치유야성위가능。위경다적애자병환자제공경고효적항병독치료시목전개선애자병환자예후적최현실도경。
HIV-1/AIDS has been transformed from a fatal disease to a treatable chronic one due to the implementation and wide use of antiretroviral therapy (ART). New progress has been made in ART in recent years along with the advances in clinical and basic research for HIV-1/AIDS, and many new ideas on the timing, regimens and follow-up of ART, and ART for special populations and patients with coinfections have been suggested. Nowadays people agree that all AIDS patients should receive ART as early as possible while some new choices of ART for HIV-1/AIDS can be available for patients with the marketing of some new antiviral drugs. The advances in the clinical research, especially a large-scale randomized clinical trial results, will constantly update and optimize ART regimens, and continuously improve the clinical curative effect of ART, which will make it possible to cure HIV-1/AIDS. Currently, the most realistic way to improve prognosis of patients with AIDS is to provide a high quality of ART for HIV-1/AIDS patients.